Agreed! It is a risk/reward. In many cases, assuming a more "clearly defined" company, there are fairly decent projections, data, and analyst opinions that can guide an investor. Then there are the development stage companies for which the investor can only make an "educated guess" about the future. In this vein, as mentioned, IMO Tauriga Sciences and the Pilus business are very similar to a development stage biotech, i.e. high risk, high reward. Since most everything is "new" from a commercialization perspective, the investment is based upon significant "speculation," given a limited set of actual knowns. The management group is becoming "known," but the science is still new. With Honeywood, I have no guess as to what the relationship and any future business might contribute. The point is the stock price, as it is today, might well be a function of "not knowing" and will remain in the current range until there is a more definitive picture of the business situation. Currently, TAUG is a $14 million market cap, using equity placements to provide cash, and is working on some "interesting," but very new business ventures. Is the share price high or low or just about right? IMO...just about right.
News 
Market Data 
Discover 
AI
